Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice

• Príomhchruthaitheoirí: Sang Bum Suh (Údar), Nayoung Lee (Údar), Jaedeok Kim (Údar), Saeha Kim (Údar), Sooyeon Jang (Údar), Jong Kook Park (Údar), Keunwook Lee (Údar), Soo Young Choi (Údar), Hyung-Joo Kwon (Údar), Chan Hee Lee (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Olanzapine (OLZ), a widely used second-generation antipsychotic drug, is known to cause metabolic side effects, including diabetes and obesity. Interestingly, OLZ-induced metabolic side effects have been demonstrated to be more profound in females in human studies and animal models. Metformin (MET)...